Cancer Statistics, 2004

Jemal, Ahmedin; Tiwari, Ram C.; Murray, Taylor; Ghafoor, Asma; Samuels, Alicia; Ward, Elizabeth; Feuer, Eric J.; Thun, Michael J.

doi:10.3322/canjclin.54.1.8

Cited by 3,843 publications

(2,277 citation statements)

References 8 publications

Supporting

Mentioning

2,182

Contrasting

Unclassified

Order By: Relevance

“…However, the long-term survival among the patients with an advanced disease (stage III or IV) is still low 1 and ovarian cancer has the highest mortality of gynecological malignancies. 2 Solid tumors require the formation of new vessels for growth and metastasis. 3 Angiogenesis, formation of new blood vessels, is controlled by proangiogenic growth factors and antiangiogenic molecules.…”

Section: Introductionmentioning

confidence: 99%

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

et al. 2010

View full text Add to dashboard Cite

Despite optimal surgery and chemotherapy, the prognosis of ovarian cancer patients remains poor and new treatments are urgently needed. Solid tumors require the formation of new vessels for growth and metastasis. In the present study, we have used soluble vascular endothelial growth factor (sVEGF) receptors sVEGFR-1 and -3, soluble receptors Tie1 and Tie2 and their combinations in an ovarian cancer xenograft model. Human ovarian cancer cells were injected intraperitoneally into nude mice (n ¼ 42) and magnetic resonance imaging (MRI) was used for confirming tumors before gene delivery. Treatment with combined AdsVEGFR-1, AdsVEGFR-3 and AdsTie2 significantly decreased the size of the intraperitoneal tumors compared with the controls (AdLacZ; P ¼ 0.038) with significantly less microvessels and vascular area. Unexpectedly, treatment with combined AdsTie1 and AdsTie2 led to a dramatic shortening of the survival which was not observed in the groups receiving either of the soluble receptors alone (P ¼ 0.031). The only difference to other treatments was liver toxicity observed after the combined Tie receptor treatment.In conclusion, combined inhibition of VEGFR-1, VEGFR-3 and Tie2 pathways was safe and provided efficient therapy for ovarian cancer in mice.

show abstract

Section: Introductionmentioning

confidence: 99%

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In addition, 29 900 cancer deaths are expected to result from prostate cancer this year, making it the second leading cause of cancer death in males. 1 Although the prevalence of latent or indolent prostate cancer does not appear to differ greatly throughout the world, the occurrence rates of clinically significant prostate cancer and mortality rates do differ significantly between Asian and Western populations. This difference has been proposed to be attributable to the dietary consumption of abundant amounts of plant-based foods in Asia, foods that are often also rich in phytochemicals.…”

Section: Introductionmentioning

confidence: 99%

The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo

Hong

Ahn

Bae

et al. 2006

Prostate Cancer Prostatic Dis

152

View full text Add to dashboard Cite

Curcumin has become a focus of interest with regard to its antitumor effects in prostate cancer; however, the effects of this agent on invasion and metastasis remain less well understood. Matrix metalloproteinases (MMPs) are important prerequisite for tumor invasion and metastasis. In this study, we evaluated the effects of curcumin on prostate cancer cells (DU-145) invasion in both in vitro and in vivo. We utilized zymography and ELISA in order to determine the MMP-2 and MMP-9 activity. Matrigel invasion assay was performed to assess cellular invasion. We developed a xenograft model to examine tumorigenicity. Curcumin treatment resulted not only in a significant reduction in the expression of MMP-2 and MMP-9, but also effected the inhibition of invasive ability in vitro. Curcumin was shown to induce a marked reduction of tumor volume, MMP-2, and MMP-9 activity in the tumor-bearing site. The metastatic nodules in vivo were significantly fewer in the curcumintreated group than untreated group. Curcumin appears to constitute a potential agent for the prevention of cancer progression, or at least of the initial phase of metastasis, in prostate cancer.

show abstract

“…British Journal of Cancer (2006) (Jemal et al, 2004), and also in Korea (Shin et al, 2004). The proportion of histologic diagnosis with small-cell lung cancer (SCLC) in the United States is approximately 15% of patients with lung cancer (Jemal et al, 2004), and more than half of these patients are diagnosed with extensive-stage disease. Incidence of SCLC had paralleled trends in cigarette smoking, and smoking prevalence for the adult population is relatively high in Korea.…”

mentioning

confidence: 99%

“…Lung cancer is the leading cause of cancer-related deaths in Western countries (Jemal et al, 2004), and also in Korea (Shin et al, 2004). The proportion of histologic diagnosis with small-cell lung cancer (SCLC) in the United States is approximately 15% of patients with lung cancer (Jemal et al, 2004), and more than half of these patients are diagnosed with extensive-stage disease.…”

mentioning

confidence: 99%

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

Park

et al. 2006

Br J Cancer

View full text Add to dashboard Cite

Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and toxicity of 3-week schedule of irinotecan/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. The primary objective was to evaluate response rate and secondary objectives were overall survival and progression-free survival. Patients with previously untreated extensive-stage small-cell lung cancer were enrolled. Irinotecan 65 mg m À2 was administered on days 1 and 8 and cisplatin 60 mg m À2 on day 1. Treatment was repeated every 3 weeks. Seven out of 54 patients (13.0%) had complete response, and partial response was observed in 33 (61.1%). The overall response rate was 74.1% (95% CI; 62.0 -82.2%). Stable disease was observed in eight (14.8%) and no progressive disease was observed. After a median follow-up duration of 28.7 months, the median overall survival and progressive-free survival were 13.6 and 6.5 months, respectively. Major grade 3/4 toxicities were neutropenia (50.0%), anorexia (42.6%), diarrhoea (29.6%), fatigue (29.6%) and vomiting (13.0%). There was one treatment-related death owing to pneumonia. Three-week schedule of irinotecan/cisplatin showed effective antitumour activity and moderate toxicities in patients with previously untreated extensive-stage small-cell lung cancer. British Journal of Cancer (2006) (Jemal et al, 2004), and also in Korea (Shin et al, 2004). The proportion of histologic diagnosis with small-cell lung cancer (SCLC) in the United States is approximately 15% of patients with lung cancer (Jemal et al, 2004), and more than half of these patients are diagnosed with extensive-stage disease. Incidence of SCLC had paralleled trends in cigarette smoking, and smoking prevalence for the adult population is relatively high in Korea. During the last decade, most patients with extensivestage SCLC (ES-SCLC) have been treated with etoposide and platinum resulting in a median survival of 8 -10 months (Roth et al, 1992). Although several trials of platinum-based combination chemotherapy were performed, it failed to show a superiority to combination of etoposide and cisplatin (EP) (Mavroudis et al, 2001;Sundstrom et al, 2002).Irinotecan, which inhibits the function of topoisomerase I in cancer cells, demonstrated synergism and non-cross resistance when combined with platinum agents (Fukuda et al, 1996;Masuda et al, 1996). Kudoh et al (1998) reported that combination chemotherapy of irinotecan and cisplatin (IP) in patients with SCLC showed a promising response rate of 84 with 29% of complete responses and median survival over 13 months. Since then, several phase II/III trials of irinotecan-based combination chemotherapy with different dose and schedule were performed with varying results in SCLC patients (Noda et al, 2002;Kudoh et al, 2005;Hanna et al, 2006;Kinoshita et al, 2006;Schmittel et al, 2006). In...

show abstract

Cancer Statistics, 2004

Cited by 3,843 publications

References 8 publications

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

Contact Info

Product

Resources

About